Phase 3 N=24 Allograft Transplantation in the Treatment of Osteoarthritis of the Metatarsophalangeal (MTP) Joint of the Great Toe
Osteoarthritis
Primary: Allograft Stability — 0
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=40 An RCT Comparing Xenograft and Allograft for Ridge Preservation
Tooth Loss
Primary: Bone Ridge Buccal-Lingual and Apico-Coronal Measures at 6 Months — 4.95; 6.71; 5.29; 6.24 mm
N/A N=27 Implant Placement With Simultaneous Gum Grafting
Edentulous
Primary: Soft Tissue Thickness Over the Implant — 0.6; 0.4 mm
Phase 3 N=26 Changes of Soft and Hard Tissues After Alveolar Ridge Preservation: Freeze-dried Bone Allograft vs. L-PRF Clot
Alveolar Bone Loss · Tooth Loss
Primary: Overall Horizontal Change in Alveolar Ridge Width — -1.34; -2.21 Millimeters
Phase 2 N=15 StrataGraft™ Skin Tissue (Human Donor Skin) In The Surgical Management Of Complex Skin Defects
Third Degree Burn · Burns · Wound Infection
Primary: Percent Autograft Take on Wounds Prepared by StrataGraft™ Skin Tissue. — 97.7; 96.7 Percent Area of Autograft Take (%)
N/A N=22 Bone Augmentation Techniques in Extraction Sockets
Tooth Loss
Primary: Changes in Hard Tissue Composition — 35.82; 31.76 mm
N/A N=51 CopiOs® Pericardium Membrane for Localized Alveolar Ridge Augmentation
Alveolar Ridge Defect
Primary: Change in Horizontal Ridge Widths From Baseline to 6 Months — 2.61 mm
N/A N=43 Ridge Preservation Following Tooth Extraction Using Two Mineralized Cancellous Bone Allografts
Alveolar Bone Loss
Primary: % Vital Bone Formation (Histological) — 27.19; 24.08 percentage
N/A N=37 The Influence of Bone Allograft Particle Sizes on the Quantity and Quality of New Bone Formation in Grafted Extraction Sockets and Edentulous Ridges
Alveolar Ridge Augmentation · Alveolar Ridge Preservation
Primary: New Bone Formation (in %) With the Use of Small vs. Large Particle Bone Allografts — 17.3; 25.9; 41.0; 31.4 % of new bone
N/A N=66 Histological Evaluation of Healing Following Ridge Preservation Using a Combined Cortical/Cancellous Mineralized Freeze-Dried Bone Allograft
Alveolar Bone Loss
Primary: % Vital Bone Formation (Histological) — 26.4; 24.5; 28.8 percentage of total area
Phase 4 N=67 Evaluation of Biocleanse Allografts For ACL Reconstruction
Anterior Cruciate Ligament Tear
Primary: International Knee Documentation Committee (IKDC) Form — 89; 88 score
N/A N=8 Case Series of New Alloplastic Bone Graft Material
Periodontology · Oral Surgery
Primary: Percentage Change in Radiographic Measurement of Alveolar Ridge Height — 1.2 percentage of change
N/A N=24 Ridge Preservation Comparing an Intrasocket Graft Alone to an Intrasocket Graft Plus a Facial Overlay Graft
Clinical Efficacy
Primary: Horizontal Ridge Dimension — -1.6; -0.3 mm
N/A N=27 A Prospective Study: Alveolar Ridge Augmentation Using Tenting Screws, Acellular Dermal Matrix and Combination Particulate Grafts
Dental Alveolus · Oral Surgical Procedures, Preprosthetic
Primary: Gain in Horizontal Ridge Dimension — 3.33; 3.09 gain in ridge width (mm)
N/A N=40 Ridge Preservation After Tooth Extraction Using Cortical Versus Cancellous Freeze Dried Bone Allograft
Tooth Extraction
Primary: Histologic Percentage of Vital Bone Formation — 12.98; 16.08 percentage of vital bone
N/A N=4 Amnion-Chorion Allograft Barrier Used for Root Surface and Guided Tissue Regeneration
Periodontal Diseases
Primary: Probing Depth Change — 4.22 millimeter
Phase 3 N=220 Comparison of Processed Nerve Allograft and Collagen Nerve Cuffs for Peripheral Nerve Repair
Peripheral Nerve Discontinuities
Primary: Static Two-Point Discrimination (Pre-defined Mixed Modeling Approach) — 9.1; 9.3 Millimeters
N/A N=19 Clinical and Histological Outcomes of Allogenic Amnion Chorion Membrane in the Healing of Free Gingival Graft Donor Site
Palatal Wound
Primary: Size of Wound Area — 80; 80 micrometers (μm)
Phase 3 N=9 Evaluation of the CR Plug for Repair of Defects Created at the Harvest Site From an Autograft in the Knee.
Knee Injury
Primary: MRI to Evaluate Success of Outcome. — 88.6 units on a scale
Phase 2 N=20 Allogeneic Transplant in HIV Patients (BMT CTN 0903)
Leukemia · Lymphoma · HIV
Primary: Percentage of Participants With Non-Relapse Mortality — 0.0; 11.8; 18.3 percentage of participants
Phase 3 N=1 StrataGraft Safety, Tolerability and Efficacy in Pediatric Subjects
Skin Wound · Burns · Trauma-related Wound
Primary: Percentage of Participants Who Achieved Confirmed Complete Closure of StrataGraft Treatment Sites Without Autograft Within 12 Weeks of StrataGraft Application — 100…
Phase 2 N=22 Phase 1/2a Study on Allogeneic Osteoblastic Cells Implantation in Delayed-Union Fractures
Long Bone Delayed-Union Fracture
Primary: Percentage of Responders at 6 Months (Efficacy of ALLOB) — 100 percent of patients
Phase 4 N=20 Comparison of Two Different Surgical Approaches To Increase Peri-Implant Mucosa Thickness
Tooth Loss · Peri-implant Mucosa Defect
Primary: Change in Buccal Peri-implant Mucosa Thickness Between Baseline and 16 Weeks After Surgery — 0.44; 0.05 millimeters
N/A N=62 The Use of Alloderm Versus Dermacell in Immediate Implant Based Breast Reconstruction
Breast Reconstruction
Primary: Postoperative Duration of Drain Placements — 9.2; 10.8 days — p=0.15
Phase 4 N=9 Acellular Dermal Matrix in Tissue Expander Breast Reconstruction: A Prospective, Randomized, Clinical Trial Comparing SurgiMend PRS and AlloDerm RTU
Breast Cancer · Mastectomy
Primary: Complication Rates — 4; 3 Participants
Phase 3 N=52 StrataGraft® Skin Tissue Expanded Access at Specific Study Sites ( StrataCAT )
Deep Partial-thickness Burn
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 46 Participants
N/A N=30 Xenogeneic Collagen Matrix as an Alternative to Free Gingival Grafting for Oral Soft Tissue Augmentation
Gingival Diseases
Primary: Keratinized Tissue Width — 4.42; 2.92 mm — p=<0.0001
N/A N=44 Ridge Preservation Following Tooth Extraction Using Porcine and Bovine Xenograft Materials
Alveolar Bone Loss
Primary: % Vital Bone Formation (Histological) — 31.27; 36.21 % vital bone
Phase 3 N=7 Allogeneic Transplantation For Severe Osteopetrosis
Severe Osteopetrosis
Primary: Number of Patients Who Achieved Donor Cell Engraftment — 5; 0 Participants
Phase 2 N=23 Autologous and Allogeneic Transplant for Relapsed Lymphoma
Non-Hodgkin's Lymphoma · Hodgkins Disease
Primary: Total Number of Subjects With a Complete Response (CR) Following Myeloablative Conditioning (MAC) and Autologous Stem Cell Transplantation (AutoSCT) — 4; 12 Participants